UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Treatment of rheumatoid vasculitis

Author
Patrick Whelan, MD, PhD
Section Editor
Eric L Matteson, MD, MPH
Deputy Editor
Paul L Romain, MD

INTRODUCTION

Rheumatoid vasculitis (RV) is a protean, inflammatory process in patients with rheumatoid arthritis (RA) that is centered on the blood vessel wall itself. RV has a range of disease severity; in some patients, it is associated with substantial morbidity and an increased risk of mortality and can require intensive immunosuppressive therapy.

RV typically occurs in patients with longstanding, erosive RA and may affect a wide range of blood vessel types, from medium-sized muscular arteries to somewhat smaller arterioles or post-capillary venules. Clinical features of both medium- and small-vessel disease may be found within a given patient, and RV is generally classified among the forms of vasculitis associated with systemic diseases rather than based upon the size of the vessels involved. (See "Overview of and approach to the vasculitides in adults", section on 'Vasculitis associated with systemic disease'.)

RV may lead to blood vessel occlusion, necrosis, and tissue ischemia in a manner that resembles other forms of systemic vasculitis. In its tendency to affect medium-sized arteries and involve the skin, peripheral nerves, eyes, heart, muscles, and other organs, RV often has a clinical appearance similar to polyarteritis nodosa (PAN). Treatment practices for RV have been adapted from those for other better studied forms of systemic vasculitis, particularly granulomatosis with polyangiitis (GPA; Wegener's), with which it also shares a number of features. (See "Clinical manifestations and diagnosis of polyarteritis nodosa in adults" and "Clinical manifestations and diagnosis of granulomatosis with polyangiitis and microscopic polyangiitis".)

The treatment of RV is presented here. The pathogenesis, clinical manifestations, and diagnosis of RV are presented separately. (See "Etiology and pathogenesis of rheumatoid vasculitis" and "Clinical manifestations and diagnosis of rheumatoid vasculitis".)

GENERAL PRINCIPLES

In determining treatment approaches for the patient with rheumatoid vasculitis (RV), an understanding of the clinical context in which this extraarticular manifestation of rheumatoid arthritis (RA) occurs is essential. The typical patient with RV has suffered from RA for at least a decade before systemic vasculitis becomes apparent. Consequently, at the time of RV onset, intensive and potentially toxic treatments will often be required in patients who have already incurred considerable morbidity from RA and its therapies. (See "Clinical manifestations and diagnosis of rheumatoid vasculitis", section on 'Clinical presentation'.)

                                  

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Apr 2017. | This topic last updated: May 04, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. CRUICKSHANK B. The arteritis of rheumatoid arthritis. Ann Rheum Dis 1954; 13:136.
  2. Suzuki A, Ohosone Y, Obana M, et al. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol 1994; 21:33.
  3. Myasoedova E, Crowson CS, Turesson C, et al. Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995-2007 versus 1985-1994: a population-based study. J Rheumatol 2011; 38:983.
  4. Hochberg MC, Johnston SS, John AK. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr Med Res Opin 2008; 24:469.
  5. Bywaters EG. A Variant of Rheumatoid Arthritis resembling Palindromic Rheumatism. Ann Rheum Dis 1949; 8:1.
  6. Watts RA, Carruthers DM, Scott DG. Isolated nail fold vasculitis in rheumatoid arthritis. Ann Rheum Dis 1995; 54:927.
  7. Price-Forbes AN, Watts RA, Lane SE, et al. Do we need to treat isolated nailfold vasculitis (NFV) in rheumatoid arthritis (RA) more aggressively? Abstract 848, American College of Rheumatology annual scientific meeting, October 2002.
  8. Watts RA, Scott DG. Vasculitis and inflammatory arthritis. Best Pract Res Clin Rheumatol 2016; 30:916.
  9. Seitz CS, Berens N, Bröcker EB, Trautmann A. Leg ulceration in rheumatoid arthritis--an underreported multicausal complication with considerable morbidity: analysis of thirty-six patients and review of the literature. Dermatology 2010; 220:268.
  10. Scott FI, Mamtani R, Brensinger CM, et al. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer. JAMA Dermatol 2016; 152:164.
  11. Mandelin J, Eklund KK, Reitamo S. Leg ulcers treated with topical tacrolimus in patients with rheumatoid arthritis. Acta Derm Venereol 2010; 90:633.
  12. Oien RF, Håkansson A, Hansen BU. Leg ulcers in patients with rheumatoid arthritis--a prospective study of aetiology, wound healing and pain reduction after pinch grafting. Rheumatology (Oxford) 2001; 40:816.
  13. Gorson KC. Vasculitic neuropathies: an update. Neurologist 2007; 13:12.
  14. Scott DG, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med 1984; 76:377.
  15. Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. Ophthalmology 1984; 91:1253.
  16. Messmer EM, Foster CS. Destructive corneal and scleral disease associated with rheumatoid arthritis. Medical and surgical management. Cornea 1995; 14:408.
  17. Breedveld FC. Vasculitis associated with connective tissue disease. Baillieres Clin Rheumatol 1997; 11:315.
  18. Abel T, Andrews BS, Cunningham PH, et al. Rheumatoid vasculitis: effect of cyclophosphamide on the clinical course and levels of circulating immune complexes. Ann Intern Med 1980; 93:407.
  19. Puéchal X, Gottenberg JE, Berthelot JM, et al. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: Results from the AutoImmunity and Rituximab Registry. Arthritis Care Res (Hoboken) 2012; 64:331.
  20. Heurkens AH, Westedt ML, Breedveld FC. Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis. Arch Intern Med 1991; 151:2249.
  21. Nicholls A, Snaith ML, Maini RN, Scott JT. Proceedings: Controlled trial of azathioprine in rheumatoid vasculitis. Ann Rheum Dis 1973; 32:589.
  22. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351.
  23. Hoffman GS, Cinta-Cid M, Rendt KE, et al. Prednisone and Infliximab for Giant Cell Arteritis: A Randomized, Double-blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety. Ann Intern Med 2006.
  24. Puéchal X, Miceli-Richard C, Mejjad O, et al. Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. Ann Rheum Dis 2008; 67:880.
  25. Carvajal Alegria G, Uguen A, Genestet S, et al. New onset of rheumatoid vasculitis during abatacept therapy and subsequent improvement after rituximab. Joint Bone Spine 2016; 83:605.
  26. Savolainen HA. Chlorambucil in severe juvenile chronic arthritis: longterm followup with special reference to amyloidosis. J Rheumatol 1999; 26:898.
  27. Karlson EW, Lee IM, Cook NR, et al. A retrospective cohort study of cigarette smoking and risk of rheumatoid arthritis in female health professionals. Arthritis Rheum 1999; 42:910.
  28. Struthers GR, Scott DL, Delamere JP, et al. Smoking and rheumatoid vasculitis. Rheumatol Int 1981; 1:145.
  29. Albano SA, Santana-Sahagun E, Weisman MH. Cigarette smoking and rheumatoid arthritis. Semin Arthritis Rheum 2001; 31:146.
  30. Kaneko S, Yamashita H, Sugimori Y, et al. Rheumatoid arthritis-associated aortitis: a case report and literature review. Springerplus 2014; 3:509.
  31. García-Martínez A, Prieto-González S, Giménez PA, et al. Aortitis and aortic aneurysm in systemic vasculitis. In: Etiology, Pathogenesis and Pathophysiology of Aortic Aneurysms and Aneurysm Rupture, Grundmann R. (Ed), InTech, 2011.
  32. Rojo-Leyva F, Ratliff NB, Cosgrove DM 3rd, Hoffman GS. Study of 52 patients with idiopathic aortitis from a cohort of 1,204 surgical cases. Arthritis Rheum 2000; 43:901.
  33. Gravallese EM, Corson JM, Coblyn JS, et al. Rheumatoid aortitis: a rarely recognized but clinically significant entity. Medicine (Baltimore) 1989; 68:95.
  34. Slobodin G, Naschitz JE, Zuckerman E, et al. Aortic involvement in rheumatic diseases. Clin Exp Rheumatol 2006; 24:S41.
  35. Voskuyl AE, Zwinderman AH, Westedt ML, et al. The mortality of rheumatoid vasculitis compared with rheumatoid arthritis. Arthritis Rheum 1996; 39:266.
  36. Puéchal X, Said G, Hilliquin P, et al. Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis. A clinicopathologic and prognostic study of thirty-two patients. Arthritis Rheum 1995; 38:1618.
  37. Makol A, Crowson CS, Wetter DA, et al. Vasculitis associated with rheumatoid arthritis: a case-control study. Rheumatology (Oxford) 2014; 53:890.
  38. Ntatsaki E, Mooney J, Scott DG, Watts RA. Systemic rheumatoid vasculitis in the era of modern immunosuppressive therapy. Rheumatology (Oxford) 2014; 53:145.
  39. Scott DG, Bacon PA, Tribe CR. Systemic rheumatoid vasculitis: a clinical and laboratory study of 50 cases. Medicine (Baltimore) 1981; 60:288.